/ROQ.L

ROQ.L Stock - Roquefort Therapeutics plc

Q: What is the analyst price target for ROQ.L?

Analyst price target information is not currently available for ROQ.L.

Q: What is ROQ.L's market cap?

Market capitalization information is not currently available for ROQ.L.

Healthcare|Biotechnology|LSE

$1.30+0.00%

+$0.00 (+0.00%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.43

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ROQ.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.43

52W High$5.50

52W Low$1.08

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	$200,000	N/A	$719
Gross Profit	$-16,000	$200,000	N/A	$-9,350
Gross Margin	N/A	100.0%	N/A	-1300.4%
Operating Income	$-1,111,515	$-1,933,644	$-1,634,303	$-510,769
Net Income	$-971,803	$-1,744,540	$-1,615,417	$-917,433
Net Margin	N/A	-872.3%	N/A	-127598.5%
EPS	$-0.01	$-0.01	$-0.02	$-0.04

Company Overview

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Visit Website

Earnings History & Surprises

ROQ.L

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.00

Q3 2025

EPS Surprise History

Q2 21

No data

Q4 21

No data

Q2 22

No data

Q2 23

No data

Q3 23

No data

Q2 24

No data

Q3 24

No data

Q3 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 28, 2026	—	—	—	—
Q3 2025	Sep 25, 2025	—	$-0.00	—	—
Q2 2025	Apr 30, 2025	—	—	—	—
Q3 2024	Sep 27, 2024	—	$-0.00	—	—
Q2 2024	Apr 26, 2024	—	$-0.01	—	—
Q3 2023	Sep 27, 2023	—	$-0.01	—	—
Q2 2023	Jun 5, 2023	—	$-0.01	—	—
Q2 2022	Jun 30, 2022	—	$-0.02	—	—
Q4 2021	Dec 31, 2021	—	$-0.01	—	—
Q2 2021	Jun 30, 2021	—	$-0.02	—	—
Q4 2020	Nov 30, 2020	—	$-0.00	—	—

Frequently Asked Questions about ROQ.L

What is ROQ.L's current stock price?

Roquefort Therapeutics plc (ROQ.L) is currently trading at $1.30 per share. The stock has moved +0.00% today.

What is the analyst price target for ROQ.L?

No analyst price targets are currently available for this stock.

What sector is Roquefort Therapeutics plc in?

Roquefort Therapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.

What is ROQ.L's market cap?

Roquefort Therapeutics plc has a market capitalization of $0.00 billion, making it a small-cap company.

Does ROQ.L pay dividends?

No, Roquefort Therapeutics plc does not currently pay a dividend to shareholders.